Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma
| Autor: | Leonardo Serrano, Melanie Rosmarin, Gabriela Brenta, Cristina Faingold, Fabián Pitoia, Marta Schnitman, Carina Parisi, Wilfrido Luciani, María Agustina Urrutia, Yanina Jimena Morosán |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
Endocrinology Diabetes and Metabolism medicine.medical_treatment risk re-stratification lcsh:Medicine Bioinformatics lcsh:Diseases of the endocrine glands. Clinical endocrinology Persistence (computer science) Iodine Radioisotopes 0302 clinical medicine Risk Factors Thyroid cancer Aged 80 and over Thyroid Age Factors Middle Aged medicine.anatomical_structure Treatment Outcome 030220 oncology & carcinogenesis Thyroidectomy Female medicine.medical_specialty recurrence 030209 endocrinology & metabolism Risk Assessment Thyroglobulin elderly Disease-Free Survival Thyroid carcinoma 03 medical and health sciences Internal medicine medicine Humans Thyroid Neoplasms Pathological Aged Neoplasm Staging Retrospective Studies lcsh:RC648-665 business.industry Carcinoma lcsh:R Cancer Retrospective cohort study staging medicine.disease Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Archives of Endocrinology and Metabolism, Vol 60, Iss 4, Pp 348-354 (2016) Archives of Endocrinology and Metabolism v.60 n.4 2016 Arquivos de Endocrinologia e Metabolismo Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Archives of Endocrinology and Metabolism, Volume: 60, Issue: 4, Pages: 348-354, Published: 23 FEB 2016 |
| ISSN: | 2359-4292 |
| Popis: | Objective The reclassification of the risk according to the response to the initial treatment makes the treatment of differentiated thyroid cancer (DTC) vary in each individual. As the influence of age on this diagnostic strategy is unknown, we have decided to assess it in adults who are over 60 years of age. Subjects and methods Ninety patients with DTC above 60 years old were enrolled, with total thyroidectomy plus radioiodine ablation, negative anti-thyroglobulin antibodies, follow-up ≥ 2 years and with clinical and pathological information to classify the risk of recurrence according to ATA (American Thyroid Association) and reclassify based on the response to initial therapy according to MSKCC (Memorial Sloan Kettering Cancer Center). The structural persistence at the end of the follow-up was the gold standard of our analysis. Results The structural persistence in ATA low, intermediate and high risk categories was 0, 38, and 100%, respectively. In the intermediate group, none of those with an excellent response to the initial treatment showed structural persistence, whereas 39% of those with an incomplete/indeterminate response showed structural persistence (p < 0.01). Conclusions The re-stratification according to the response to the initial treatment in patients over 60 years of age with an ATA intermediate risk of recurrence allowed for the distinction of disease-free patients at the end of the follow-up from those with structural persistence and a worse clinical progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|